{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', \"Refer to Investigator's\", 'Brochure for', \"Investigator's\", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', '27']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', \"A participant will be withdrawn if the participant's treatment code is unblinded by the\", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', \"GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the\", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', \"report, identifying the participant's treatment assignment, may be sent to investigators in\", 'accordance with local regulations and/or GSK policy.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '28']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '(manual or automated) area in accordance with the labeled storage conditions', 'with access limited to the investigator and authorized site staff.', 'The investigator, institution, or the head of the medical institution (where', 'applicable) is responsible for study treatment accountability, reconciliation, and', 'record maintenance (ie, receipt, reconciliation, and final disposition of records).', 'Further guidance and information for the final disposition of unused study', 'treatment are provided in the SRM.', 'Precaution will be taken to avoid direct contact with the study treatment. Under', 'normal conditions of handling and administration, study treatment is not expected', 'to pose significant safety risks to site staff. In the case of unintentional', 'occupational exposure notify the monitor, Medical Monitor and/or GSK study', 'contact.', 'A Material Safety Data Sheet MSDS)/equivalent document describing', 'occupational hazards and recommended handling precautions either will be', 'provided to the investigator, where this is required by local laws, or is available', 'upon request from GSK.', '7.6.', 'Treatment Compliance', 'When participants are dosed at the site, they will receive study treatment directly', 'from the investigator or designee, under medical supervision. The date and time of', 'each dose administered in the clinic will be recorded in the source documents. The', 'dose of study treatment and study participant identification will be confirmed at the', 'time of dosing by a member of the study site staff other than the person', 'administering the study treatment.', 'When participants self-administer study treatment(s) at home, compliance with study', 'treatment administration will be assessed through querying the participant during the', 'site visits and documented in the source documents and CRF. In addition,', 'participants will be asked to confirm study administration each day in the daily', 'ediary.', 'Study participants who are not compliant with study treatment administration', 'requirements should be re-educated on the importance of treatment compliance.', 'Every effort should be made to keep participants in the study. Participants who', 'continue to be non-compliant after several attempts to re-educate may be', 'discontinued after consultation with the GSK study team.', '7.7.', 'Concomitant Therapy', 'Any medication or vaccine (including over-the-counter or prescription medicines,', 'vitamins, and/or herbal supplements) that the participant is receiving at the time of', 'enrolment or receives during the study must be recorded along with:', 'reason for use', 'dates of administration including start and end dates', '29']\n\n###\n\n", "completion": "END"}